Hypoglucemia in patients with diabetes mellitus in emergency services of two hospitals in Bogotá, 2015-2017
PDF (Español (España))
HTML (Español (España))

Keywords

Hypoglycemia
diabetes mellitus
insulin
emergencies

How to Cite

Chaves, W., Martínez, L., Díaz, D., Hernández, D., & Sanabria, M. (2019). Hypoglucemia in patients with diabetes mellitus in emergency services of two hospitals in Bogotá, 2015-2017. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 6(4), 269–276. https://doi.org/10.53853/encr.6.4.545

Abstract

Introduction: from a genotypic and phenotypic point of view, the diabetic population is heterogeneous, which makes some special groups more susceptible to complications during treatment. Among these complications, hypoglycemia is a frequent reason for consultation; however, information about episodes of this alteration is limited, especially in Latin America.
Objective: to determine the sociodemographic and clinical characteristics of diabetic patients with hypoglycemia in the emergency services of the San José hospital and the San José University Children´s hospital.
Methodology: retrospective evaluation of a cohort of diabetic patients with hypoglycemia in the emergency services from January 2015 to December 2017. A descriptive analysis of the demographic, clinical and therapeutic factors of this population was made. Data were collected from medical records and characteristics were analyzed using descriptive statistics.
Results: within the data found, 201 patients presented hypoglycemia at admission (12.5%). With a median of 70 years, 85.5% were type 2 diabetics; of these, 99% had insulin management; more frequently they used insulin glargine (58.1%) and insulin glulisine (36.3%). 36.6% used oral medications, mainly biguanides; and the most frequent combination was basal insulin plus short-acting insulin, in 56.7%. The median glucose was 40.5 mg / dL and the glycosylated hemoglobin (HbA1c) test was 6.7%. Mortality found in this population was 7.5%.
Conclusions: the prevalence of hypoglycemia in this study was low. The results suggest that the lack of individualization when choosing treatments and therapeutic objectives, could be related with the increase in episodes of severe hypoglycemia. Therefore, a patient-centered treatment should be performed, considering the presence of previous episodes, the history of cardiovascular disease, associated concomitant diseases, weight, medication costs and age

https://doi.org/10.53853/encr.6.4.545
PDF (Español (España))
HTML (Español (España))

References

1. American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73-85.
2. Emral R, Pathan F, Cortés CAY, El-Hefnawy MH, Goh S-Y, Gómez AM, et al. Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. Diabetes Res Clin Pract. 2017;134:17-28.
3. Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-95.
4. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26(4):1176-80.
5. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.
6. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2015;38(2):316-22.
7. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol. 2014;10(12):711-22.
8. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.
9. Mathur S, Zammitt NN. Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?. Drug Safety BM. 2015;38(1).
10. Brito-Sanfiel M, Diago-Cabezudo J, Calderon A. Economic impact of hypoglycemia on healthcare in Spain. Expert Rev Pharmacoecon Outcomes Res. 2010;10(6):649-60.
11. Edridge CL, Dunkley AJ, Bodicoat DH, Rose TC, Gray LJ, Davies MJ, et al. Prevalence and Incidence of Hypoglycaemia in 532,542 People with Type 2 Diabetes on Oral Therapies and Insulin: A Systematic Review and MetaAnalysis of Population Based Studies. PloS One. 2015;10(6):e0126427.
12. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. marzo de 2009;94(3):709-28.
13. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med J Br Diabet Assoc. 2012;29(7):855-62.
14. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe Hypoglycemia and Risks of Vascular Events and Death. N Engl J Med. 2010;363(15):1410-8.
15. Feinkohl I, Aung PP, Keller M, Robertson CM, Morling JR, McLachlan S, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(2):507-15.
16. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, et al. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a population-based study. Diabet Med J Br Diabet Assoc. 2005;22(6):749-55.
17. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140-7.
18. ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW. Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care. 2000;23(10):1467-71.
19. Cecilia VR, San Cristóbal F, Jara P, López S, Trujillo J, Cecilia VR, et al. Caracterización de eventos de hipoglicemia en pacientes diabéticos y no diabéticos atendidos en un servicio de urgencia. Rev Médica Chile. 2017;145(11):1387-93.
20. Khunti K, Alsifri S, Aronson R, Cigrovski Berkovi? M, Enters-Weijnen C, Forsén T, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907-15.
21. Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int. 2015;87(3):649-59.
22. ORIGIN Trial Investigators. Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial. Diabetes Care. 2015;38(1):22-8.
23. Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, et al. Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care. 2017;40(8):1010-6.
24. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med J Br Diabet Assoc. 2001;18(9):690-705.
25. Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med J Br Diabet Assoc. 1993;10(3):231-7.
26. Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med J Br Diabet Assoc. 2014;31(1):92-101.
27. Orozco-Beltrán D, Artola S, Jansà M, Lopez de la Torre-Casares M, Fuster E. Impact of hypoglycemic episodes on health-related quality of life of type-2 diabetes mellitus patients: development and validation of a specific QoLHYPO© questionnaire. Health Qual Life Outcomes. 2018;16(1):52.
28. Rosenstock J, Fonseca V, Schinzel S, Dain M-P, Mullins P, Riddle M. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. J Diabetes Complications. 2014;28(5):742-9.
29. Lipska KJ, Parker MM, Moffet HH, Huang ES, Karter AJ. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. JAMA. 2018;320(1):53-62.
30. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.
31. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166(5):823- 830.e5.
32. Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18(1):82-91.
33. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011;162(5):818-825.e6.
34. Roumie CL, Min JY, Greevy RA, Grijalva CG, Hung AM, Liu X, et al. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea. CMAJ Can Med Assoc J J Assoc Medicale Can. 2016;188(6):E104-12.
35. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461-98.
36. Barranco RJ, Gomez-Peralta F, Abreu C, Delgado M, Palomares R, Romero F, et al. Incidence and care-related costs of severe hypoglycaemia requiring emergency treatment in Andalusia (Spain): the PAUEPAD project. Diabet Med J Br Diabet Assoc. 2015;32(11):1520-6.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here

Dimensions


PlumX


Downloads

Download data is not yet available.